Following the recent linkurl:failure;http://www.the-scientist.com/blog/display/53633 of a linkurl:Merck HIV vaccine,;http://www.the-scientist.com/article/display/53517 the NIH has still not decided whether to continue with planned clinical trials of a similar HIV vaccine. Yesterday (December 12), the AIDS Vaccine Research Committee of the National Institute of Allergy and Infectious Diseases met to discuss the PAVE100 study, which was suspended after linkurl:data from the Merck trials;http://www.the-scientist.com/blog/display/53845 came back. Both vaccines use an linkurl:adenovirus vector;http://www.the-scientist.com/article/display/22642 to deliver HIV genes and replicate their proteins. The data from the Merck trials suggested that the vaccine might have actually made people with pre-existing immunity to adenovirus more susceptible to HIV infection, leading to the halting of the PAVE100 trials. The sentiment at yesterday's meeting seemed to be that the vaccines are different enough to warrant going ahead with the PAVE100 study, linkurl:Anthony Fauci,;http://www.the-scientist.com/news/display/53585 the director of the National Institute of Allergy and Infectious Diseases told __The Scientist.__ The PAVE100 vaccine also...
Interested in reading more?
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?